挽救性扩大淋巴结清扫在PSA升高且PET/CT检出前列腺癌淋巴结复发患者中的作用
2009至2016年对87例前列腺癌初始治疗后生化复发且18FEC与68Ga-PSMA PET/CT显示淋巴结阳性的患者行挽救性扩大淋巴结清扫,评估并发症、生化缓解及无复发生存;完全生化缓解27.5%,中位随访21个月,3年无生化复发、无系统治疗、无临床复发生存率在完全生化缓解患者分别为69.3%、77.0%、75%。
要点
- sLND可无显著并发症完成,并实现即刻生化缓解。
- 完全生化缓解患者3年无生化复发生存率为69.3%。
- 完全生化缓解患者3年无系统治疗生存率为77.0%。
核心结论
- sLND可无显著并发症完成并实现即刻生化缓解,从而在选择性生化复发且淋巴结复发的前列腺癌患者中显著推迟系统治疗。
- 作者认为,对选择性患者,68Ga-PSMA PET/CT后的sLND应被视为多模式诊断和治疗概念的一部分。
研究设计与样本
- 2009至2016年对87例前列腺癌初始治疗后生化复发且18FEC与68Ga-PSMA PET/CT显示淋巴结阳性的患者行挽救性扩大淋巴结清扫。
- 按Clavien-Dindo评估术中及术后并发症,并评估生化缓解率、无生化复发生存、无临床复发生存及至系统治疗启动时间。
主要发现
- 患者平均年龄66.7岁(范围46-80岁),sLND时平均PSA为2.63 ng ml-1(范围1.27-3.75 ng ml-1)。
- 87.4%患者初始治疗为根治性前列腺切除术,57.9%患者额外接受辅助/挽救性放疗,18.4%患者在sLND前接受ADT。
- 完全生化缓解见于27.5%患者,不完全生化缓解见于40.6%患者;总计62.2%患者在随访时未使用ADT。
- 中位随访21个月(范围1-75个月),肿瘤特异性死亡率为3.7%。
- 完全生化缓解患者的3年无生化复发、无系统治疗及无临床复发生存率分别为69.3%、77.0%和75%。
临床怎么用
- 作者认为,对选择性生化复发且淋巴结复发的前列腺癌患者,68Ga-PSMA PET/CT后的sLND应被视为多模式诊断和治疗概念的一部分。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Non-prostatic bed recurrence of prostate cancer (PCa) is usually treated with androgen deprivation therapy (ADT). We analyzed the impact of salvage extended lymph node dissection (sLND) on cancer control in patients with rising PSA and lymph node (LN) metastases. METHODS: Between 2009 and 2016 we performed sLND in 87 patients with biochemical recurrence (BCR) and positive LNs on 18FEC and 68Ga-PSMA positron emission tomography/X-ray computer tomography (PET/CT) after primary treatment (PT) of PCa. Intra- and postoperative complications according to Clavien-Dindo were assessed and the rates of biochemical response (BR), BCR-free and clinical recurrence (CR)-free survival, as well as time to initiation of systemic treatment were evaluated. RESULTS: Mean age of patients and mean PSA at sLND was 66.7 years (46-80 years) and 2.63 ng ml-1 (1.27-3.75 ng ml-1), respectively. With 87.4% radical prostatectomy (RP) was the most common PT. In all, 57.9% of patients additionally underwent adjuvant/salvage radiation therapy (RT) and 18.4% received ADT before sLND. Complete BR (cBR) was diagnosed in 27.5% of patients and incomplete BR in 40.6%. In total, 62.2% of patients remained without ADT at follow-up. With a median follow-up of 21 months (1-75 months), the cancer-specific mortality rate was 3.7%. The 3-year BCR-free, systemic therapy-free and CR-free survival rates for patients with cBR were 69.3%, 77.0% and 75%, respectively. CONCLUSIONS: sLND can be performed without significant complications and achieves an immediate BR, thus allowing a significant postponement of systemic therapy in selected patients with BCR and nodal recurrence of PCa. Therefore, sLND following 68Ga-PSMA PET/CT should be considered as part of a multimodal diagnostic and treatment concept for selective patients.
引用
- Porres D, Pfister D, Thissen A, et al. The role of salvage extended lymph node dissection in patients with rising PSA and PET/CT scan detected nodal recurrence of prostate cancer. Prostate Cancer Prostatic Dis. 2016. PMID: 27824042. doi:10.1038/pcan.2016.54
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。